Clinical trial
Neuropathic Pain in Patients With Cancer
NCT00474916 · DARA Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00474916 |
|---|---|
| Title | Neuropathic Pain in Patients With Cancer |
| Official title | A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer |
| Lead sponsor | DARA Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuropathic Pain |
| Intervention type | Drug |
| Interventions | KRN5500, Placebo |
| Enrollment | 19 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | May 17, 2007 |
| Last update posted | Aug 16, 2010 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: